Baseline Blood Indices and Prolonged Length of Hospital Stay

NCT05054283 | Unknown

• 1 other identifier: 2020-374
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

During a pandemic, length of hospital stay (LOS) is critical to managing high patient volumes and preserves access to care related to non-COVID-19 for maintaining the healthcare system. Moreover, identification of prolonged hospital stay may allow physicians to reevaluate critical patients, focused delivery of specific interventions, and improve the efficiency of hospital care. Furthermore, in previous recent studies, attention has been paid to patients with diabetes and COVID-19 infection may require a prolonged LOS. However, there is little evidence on prognostic factors associated with an extension of hospitalization in mild or moderate illness due to COVID-19 infection. Therefore, it is crucial to determine the most vulnerable patients with diabetes mellitus even if they have a non-severe COVID-19 infection during the pandemic. We hypothesize that the clinically relevant inflammatory parameters may have an impact on LOS in older adults with diabetes and non-severe COVID-19 infection. Therefore, we aim to investigate whether baseline inflammatory parameters on admission hospitals as possible predictors of prolonged LOS in older adults with diabetes and non-severe COVID-19 infection during the pandemic.

Conditions

Hospitalism; COVID-19 Pneumonia; Diabetes Mellitus, Type 2

Keywords

Length of hospital stay; Covid-19 Pneumonia; Diabetes Mellitus

Outcome Measures

Primary Outcomes (1)

• Prolonged Length of hospital

  The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization.

  at least 2 week

Study Arms (2)

Length of hospital Stay (normal)

The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.

Diagnostic Test: Inflamatory biomarkers

Length of hospital Stay (prolonged)

The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.

Diagnostic Test: Inflamatory biomarkers

Interventions

Inflamatory biomarkers DIAGNOSTIC_TEST

laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.

Length of hospital Stay (normal); Length of hospital Stay (prolonged)

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The date of hospital admission and discharge of patients and baseline clinical characteristics including age, sex, comorbidities (hypertension, cardiovascular disease, chronic obstructive pulmonary disease and others), diabetes medications (oral anti-diabetic drugs or insulin), and laboratuary parameters of within 24 hours of admission (levels of white blood cell (WBC), lymphocyte neutrophil, hemoglobin (Hb), platelet, fasting glucose, glycated hemoglobin, aspartate aminotransferase (AST) , c-reactive protein (CRP), ferritin, and procalcitonin) were recorded from medical records and collected by two trained fellow geriatricians.

You may qualify if:

• We included all hospitalized Covid-19 patients with diabetes mellitus according to the any established diagnosis prior to admission or American Diabetes Association guidelines for diagnostic criteria

You may not qualify if:

• The patients with severe Covid-19 infection, secondary diabetes or type 1 diabetes mellitus were excluded.

Sponsors & Collaborators

• Gulhane Training and Research Hospital: lead

Study Sites (1)

Gulhane training and research hospital

Ankara, 06670, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Diabetes Mellitus, Type 2; Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Central Study Contacts

Bilal KATIPOGLU, MD

CONTACT

5543330380; drbilal07@gmail.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Geriatrics

Study Record Dates

• First Submitted: September 14, 2021
• First Posted: September 23, 2021
• Study Start: October 1, 2021
• Primary Completion: November 1, 2021
• Study Completion: December 1, 2021
• Last Updated: September 23, 2021

Record last verified: 2021-09

Locations

TU (1)